PCSK9 regulates the efficacy of immune checkpoint therapy in lung cancer

Proprotein convertase subtilisin/kexin type 9 (PCSK9) secreted by tumors was reported as a deleterious factor that led to the reduction of lymphocyte infiltration and the poorer efficacy of ICIs in vivo. This study aimed to explore whether PCSK9 expression in tumor tissue could predict the response...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Xiang, Yi, Ling, Jiang, Chang, Li, Shuping, Wang, Xiaojue, Yang, Bin, Li, Weiying, Che, Nanying, Wang, Jinghui, Zhang, Hongtao, Zhang, Shucai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070680/
https://www.ncbi.nlm.nih.gov/pubmed/37025995
http://dx.doi.org/10.3389/fimmu.2023.1142428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070680/
https://www.ncbi.nlm.nih.gov/pubmed/37025995
http://dx.doi.org/10.3389/fimmu.2023.1142428

Ejemplares similares